Early identification of acute heart failure at the time of presentation: do natriuretic peptides make the difference?

ABSTRACT:

Background

The early identification of patients with acute heart failure (AHF) is challenging as many other diseases lead to a clinical presentation with dyspnea.

Aim

The aim of the study was to evaluate the impact of natriuretic peptides at common HF study cut-offs on the diagnosis of patients with dyspnea at admission.

Methods and results

For this post hoc analysis, we analysed n = 726 European Union (EU) patients from the prospective BACH (Biomarkers in Acute Heart Failure) study. Cut-offs were 350 ng/L (BNP), 300 pmol/L [pro-atrial natriuretic peptide (proANP)], and 1800 ng/L (NT-proBNP). These cut-offs had equivalent 90 days' mortality in the EU cohort of BACH. We analysed the effect of selection using these cut-offs on the prevalence of the gold standard diagnos

SUBMITTER: Mockel M 

PROVIDER: S-EPMC5933954 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature